|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Vitamin D supplementation in pregnant women or infants for preventing allergic diseases:a systematic review and meta-analysis of randomized controlled trials显示文摘Background:It is still unclear if and to what extent antenatal or infant or childhood vitamin D supplementation would affect the development of allergy diseases later in life.This study aimed to review the efficacy of vitamin D supplementation in pregnant women,infants,or children for the prevention of allergies.Methods:MEDLINE(PubMed),EMBASE(OVID),and the Cochrane Central Register of Controlled Trials were searched up to March 1,2020.We included only randomized controlled trials(RCTs).We performed a systematic review and meta-analysis for vitamin D supplementation in primary allergy prevention.These trials were assessed for risk of bias using the Cochrane Collaboration domains and the consensus was reached via discussion with the full study group.We descriptively summarized and quantitatively synthesized original data to evaluate vitamin D supplementation in primary allergy prevention by using Review Manager software for meta-analysis.Results:The search yielded 1251 studies.Seven RCTs were included in this analysis.A meta-analysis revealed that vitamin D supplementation for pregnant women or infants may not decrease the risk of developing allergic diseases,such as asthma or wheezing(supplementation for pregnant women,risk ratio[RR]:1.01,95%confidence interval[CI]:0.81-1.26,P=0.90,I^(2)=47%;supplementation for infants,RR:1.00,95%CI:0.70-1.43,P=0.99,I2=0%;supplementation for pregnant women and infants,RR:0.35,95%CI:0.10-1.25,P=0.11),eczema(supplementation for pregnant women,RR:0.95,95%CI:0.80-1.13,P=0.77,I^(2)=0%;supplementation for infants,RR:0.84,95%CI:0.64-1.11,P=0.19,I2=42%),allergic rhinitis(supplementation for pregnant women,RR:0.93,95%CI:0.78-1.11,P=0.15,I^(2)=47%),lower respiratory tract infection(LRTI)(supplementation for pregnant women,RR:0.97,95%CI:0.85-1.11,P=0.59,I^(2)=0%),or food allergy.Conclusions:Supplementation of vitamin D in pregnant women or infants does not have an effect on the primary prevention of allergic diseases. | Chao Luo Yaning Sun Zuojing Zeng Ying Liu Shunlin Peng | 2022 | Chinese Medical Journal2022，，3： | 3 |
| 2 | Increased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis显示文摘Dysregulation of the gut microbiota/gut hormone axis contributes to the pathogenesis of irritable bowel syndrome(IBS).Melatonin plays a beneficial role in gut motility and immunity.However,altered expression of local mucosal melatonin in IBS and its relationship with the gut microbiota remain unclear.Therefore,we aimed to detect the colonic melatonin levels and microbiota profiles in patients with diarrhea-predominant IBS(IBS-D)and explore their relationship in germ-free(GF)rats and BON-1 cells.Thirty-two IBS-D patients and twenty-eight healthy controls(HCs)were recruited.Fecal specimens from IBS-D patients and HCs were separately transplanted into GF rats by gavage.The levels of colon mucosal melatonin were assessed by immunohistochemical methods,and fecal microbiota communities were analyzed using 16S rDNA sequencing.The effect of butyrate on melatonin synthesis in BON-1 cells was evaluated by ELISA.Melatonin levels were significantly increased and negatively correlated with visceral hypersensitivity in IBS-D patients.GF rats inoculated with fecal microbiota from IBS-D patients had high colonic melatonin levels.Butyrate-producing Clostridium cluster XIVa species,such as Roseburia species and Lachnospira species,were positively related to colonic mucosal melatonin expression.Butyrate significantly increased melatonin secretion in BON-1 cells.Increased melatonin expression may be an adaptive protective mechanism in the development of IBS-D.Moreover,some Clostridium cluster XIVa species could increase melatonin expression via butyrate production.Modulation of the gut hormone/gut microbiota axis offers a promising target of interest for IBS in the future. | Ben Wang Shiwei Zhu Zuojing Liu Hui Wei Lu Zhang Meibo He Fei Pei Jindong Zhang Qinghua Sun Liping Duan | 2020 | Genomics, Proteomics & Bioinformatics2020，18，6： | 2 |
| 3 | Regeneration of ax?ons after nerve transection repair is enhanced by degradation of chondroitin sulfate proteoglycan显示文摘 | ZUOJ NEUBAUER D GRAHAMJ | 2002 | Exp Neurol2002，176，1： | 1 |
| 4 | Macromolecules显示文摘 | LI X ZUOJ GUO Y | 2004 | (37):10042-100462004，，10： | 1 |
| 5 | Improving the conversion of biomass in catalytic fast pyrolysis via white-rot fungal pretreatment 显示文摘 | YUYQ ZENGYL ZUOJ N etal | 2013 | Bioresource Technology2013，134，： | 1 |
| 6 | Chargedensityandchemicalbondinginrutile,TiO2 显示文摘 | JiangB ZuoJ M Jiang N etal | 2003 | Acta Crystallo-graphicaSectionA2003，59，： | 1 |
| 7 | Study on the quantitative structure-toxicity relationships of aconitine compounds basing on PCA-ANN method显示文摘 | Li Zuojing Wang Lin Peng Jing | 2013 | Medicinal Chemistry Research2013，，22： | 1 |
| 8 | Fudenine, a C-terminal truncated rat homologue of mouse prominin, is blood glucose-regulated and can up-regulate the expression of GAPDH 显示文摘 | Zhu G Chang Y ZuoJ | 2001 | Biochem Biophys Res Commun2001，281，： | 1 |
| 9 | Marker-freetransformation:Increasingtransformationfrequencybythe use ofregeneration-promotinggenes显示文摘 | ZUOJ NIUQW IKEDAY etal | 2002 | Current Opinion Biotech2002，13，： | 1 |
| 10 | LysGHI5 reduces the inflammation caused by lethal methicillin-resistant Staphylococcus aureus infection in mice显示文摘 | GuJ ZuoJ Lei L | 2011 | Bioengineered Bugs2011，2，2： | 1 |
| 11 | Bcl-2 overexpression induces a partial epithelial to mesenchymal transition and promotes squa- mous carcinoma cell invasion and metastasis显示文摘 | Zuoj Ishikawa T Boutros S | 2010 | Mol Cancer Res2010，8，2： | 1 |
| 12 | Chemical inducible systems for regulated expression of plant genes显示文摘 | ZuoJ Chua NH | 2000 | Cur Opin Biotech2000，11，2： | 1 |
| 13 | Neo-intline: integrated pipeline enables neoantigen design through the in-silico presentation of T-cell epitope显示文摘Neoantigen vaccines are one of the most effective immunotherapies for personalized tumour treatment.The current immunogen design of neoantigen vaccines is usually based on whole-genome sequencing(WGS)and bioinformatics prediction that focuses on the prediction of binding affinity between peptide and MHC molecules,ignoring other peptide-presenting related steps.This may result in a gap between high prediction accuracy and relatively low clinical effectiveness.In this study,we designed an integrated in-silico pipeline,Neo-intline,which started from the SNPs and indels of the tumour samples to simulate the presentation process of peptides in-vivo through an integrated calculation model.Validation on the benchmark dataset of TESLA and clinically validated neoantigens illustrated that neo-intline could outperform current state-of-the-art tools on both sample level and melanoma level.Furthermore,by taking the mouse melanoma model as an example,we verified the effectiveness of 20 neoantigens,including 10 MHC-I and 10 MHC-II peptides.The in-vitro and in-vivo experiments showed that both peptides predicted by Neo-intline could recruit corresponding CD4^(+)T cells and CD8^(+)T cells to induce a T-cell-mediated cellular immune response.Moreover,although the therapeutic effect of neoantigen vaccines alone is not sufficient,combinations with other specific therapies,such as broad-spectrum immune-enhanced adjuvants of granulocyte-macrophage colony-stimulating factor(GM-CSF)and polyinosinic-polycytidylic acid(poly(I:C)),or immune checkpoint inhibitors,such as PD-1/PD-L1 antibodies,can illustrate significant anticancer effects on melanoma.Neo-intline can be used as a benchmark process for the design and screening of immunogenic targets for neoantigen vaccines. | Bingyu Li Ping Jing Genhui Zheng Chenyu Pi Lu Zhang Zuojing Yin Lijun Xu Jingxuan Qiu Hua Gu Tianyi Qiu Jianmin Fang | 2023 | Signal Transduction and Targeted Therapy2023，8，11： | 0 |
| 14 | Patients with breath test positive are necessary to be identified from irritable bowel syndrome:a clinical trial based on microbiomics and rifaximin sensitivity显示文摘Background:As a non-invasive and effective diagnostic method for small intestinal bacterial overgrowth(SIBO),wild-use of breath test(BT)has demonstrated a high comorbidity rate in patients with diarrhea-predominant irritable bowel syndrome(IBS-D)and SIBO.Patients overlapping with SIBO respond better to rifaximin therapy than those with IBS-D only.Gut microbiota plays a critical role in both of these two diseases.We aimed to determine the microbial difference between IBS-D overlapping with/without SIBO,and to study the underlying mechanism of its sensitivity to rifaximin.Methods:Patients with IBS-D were categorized as BT-negative(IBSN)and BT-positive(IBSP).Healthy volunteers(BT-negative)were enrolled as healthy control.The patients were clinically evaluated before and after rifaximin treatment(0.4 g bid,4 weeks).Blood,intestine,and stool samples were collected for cytokine assessment and gut microbial analyses.Results:Clinical complaints and microbial abundance were significantly higher in IBSP than in IBSN.In contrast,severe systemic inflammation and more active bacterial invasion function that were associated with enrichment of opportunistic pathogens were seen in IBSN.The symptoms of IBSP patients were relieved in different degrees after therapy,but the symptoms of IBSN rarely changed.We also found that the presence of IBSN-enriched genera(Enterobacter and Enterococcus)are unaffected by rifaximin therapy.Conclusions:IBS-D patients overlapping with SIBO showed noticeably different fecal microbial composition and function compared with IBS-D only.The better response to rifaximin in those comorbid patients might associate with their different gut microbiota,which suggests that BT is necessary before IBS-D diagnosis and use of rifaximin.Registration:Chinese Clinical Trial Registry,ChiCTR1800017911. | Zuojing Liu Shiwei Zhu Meibo He Mo Li Hui Wei Lu Zhang Qinghua Sun Qiong Jia Nan Hu Yuan Fang Lijin Song Chen Zhou Heqing Tao John Y Kao Huaiqiu Zhu Chung Owyang Liping Duan | 2022 | Chinese Medical Journal2022，，14： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员